In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab, a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival ...
Recursion, whose advisers include AI pioneer Yoshua Bengio, will use its biological and chemical datasets exceeding 23,000 terabytes to train AI models on Nvidia's cloud platform. Sign up here. Nvidia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback